Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:HSCS

HeartSciences Q4 2026 Earnings Report

HeartSciences logo
$2.74 +0.06 (+2.24%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$2.70 -0.05 (-1.64%)
As of 07/10/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

HeartSciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.66
Beat/Miss
N/A
One Year Ago EPS
N/A

HeartSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.05 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

HeartSciences Announcement Details

Quarter
Q4 2026
Date
7/23/2026
Time
Before Market Opens
Conference Call Date
Friday, July 24, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

HeartSciences Earnings Headlines

Head-To-Head Analysis: Clover Health Investments (NASDAQ:CLOV) versus HeartSciences (NASDAQ:HSCS)
July 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30878774
HeartSciences Stock Short Interest Report | NASDAQ:HSCS | Benzinga
June 25, 2026  |  benzinga.comhttps://www.benzinga.com/quote/HSCS/short-interest
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
July 11 at 1:00 AM  |  Porter & Company (Ad)
HeartSciences (NASDAQ:HSCS) Stock, Earnings Estimates, EPS, And Revenue
June 24, 2026  |  benzinga.comhttps://www.benzinga.com/quote/HSCS/earnings
Zcash Miner Fortitude Merging with HeartSciences to Go Public
June 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/crypto/articles/zcash-miner-fortitude-merging-heartsciences-195641726.html
HeartSciences Surges on Planned Merger With Zcash Mining Platform Fortitude
June 23, 2026  |  quiverquant.comQ
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

View HeartSciences Profile
Earnings Tools